

Regulation (EU) No 536/2014 of the European Parliament and of the Council of 16 April 2014 on clinical trials on medicinal products for human use, and repealing Directive 2001/20/EC (Text with EEA relevance)

## CHAPTER XVI

### FEES

#### *Article 86*

#### **General principle**

This Regulation shall be without prejudice to the possibility for Member States to levy a fee for the activities set out in this Regulation, provided that the level of the fee is set in a transparent manner and on the basis of cost recovery principles. Member States may establish reduced fees for non-commercial clinical trials.

#### *Article 87*

#### **One payment per activity per Member State**

A Member State shall not require, for an assessment as referred to in Chapters II and III, multiple payments to different bodies involved in this assessment.

**Changes to legislation:**

There are currently no known outstanding effects for the Regulation (EU) No 536/2014 of the European Parliament and of the Council, CHAPTER XVI.